JP2017532371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532371A5 JP2017532371A5 JP2017532211A JP2017532211A JP2017532371A5 JP 2017532371 A5 JP2017532371 A5 JP 2017532371A5 JP 2017532211 A JP2017532211 A JP 2017532211A JP 2017532211 A JP2017532211 A JP 2017532211A JP 2017532371 A5 JP2017532371 A5 JP 2017532371A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- linear
- optionally substituted
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 88
- 125000005843 halogen group Chemical group 0.000 claims 35
- 125000001424 substituent group Chemical group 0.000 claims 33
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 239000001301 oxygen Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 229910052717 sulfur Chemical group 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 230000035508 accumulation Effects 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- -1 N-[(1S) -1- (1-benzyl-2-methoxycarbamoyl-2-oxo-ethylcarbamoyl) -3-methyl-butyl] -3-methoxy-benzamide Compound Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000006372 lipid accumulation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382332.6 | 2014-09-08 | ||
| EP14382332 | 2014-09-08 | ||
| PCT/EP2015/070504 WO2016038040A2 (en) | 2014-09-08 | 2015-09-08 | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532371A JP2017532371A (ja) | 2017-11-02 |
| JP2017532371A5 true JP2017532371A5 (enExample) | 2019-06-06 |
| JP6533580B2 JP6533580B2 (ja) | 2019-06-19 |
Family
ID=51730474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532211A Active JP6533580B2 (ja) | 2014-09-08 | 2015-09-08 | ジペプチジルケトアミド化合物ならびに脂肪蓄積の治療および／または予防のためのそれらの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10294269B2 (enExample) |
| EP (1) | EP3191112B1 (enExample) |
| JP (1) | JP6533580B2 (enExample) |
| KR (1) | KR102404113B1 (enExample) |
| CN (1) | CN107001240B (enExample) |
| AU (1) | AU2015314292B2 (enExample) |
| BR (1) | BR112017004563B1 (enExample) |
| CA (1) | CA2960432C (enExample) |
| CL (1) | CL2017000539A1 (enExample) |
| CO (1) | CO2017003067A2 (enExample) |
| CR (1) | CR20170135A (enExample) |
| DK (1) | DK3191112T3 (enExample) |
| EA (1) | EA031266B1 (enExample) |
| EC (1) | ECSP17021138A (enExample) |
| ES (1) | ES2731274T3 (enExample) |
| GT (1) | GT201700045A (enExample) |
| MX (1) | MX374875B (enExample) |
| NI (1) | NI201700026A (enExample) |
| PE (1) | PE20170918A1 (enExample) |
| PT (1) | PT3191112T (enExample) |
| SV (1) | SV2017005406A (enExample) |
| WO (1) | WO2016038040A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107290323B (zh) * | 2017-08-10 | 2020-01-14 | 台州学院 | 一种近红外荧光探针及其制备方法与应用技术 |
| EP3564211A1 (en) * | 2018-05-03 | 2019-11-06 | Landsteiner Genmed, S.L. | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650508A (en) * | 1991-12-27 | 1997-07-22 | Georgia Tech Research Corporation | Peptide ketoamides |
| US6235929B1 (en) * | 1991-12-27 | 2001-05-22 | Georgia Tech Research Corporation | Tripeptide α-ketoamides |
| EP0650368A1 (en) * | 1992-06-24 | 1995-05-03 | Cortex Pharmaceuticals, Inc. | Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
| US5514694A (en) * | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
| US5541290A (en) * | 1993-06-24 | 1996-07-30 | Harbeson; Scott L. | Optically pure calpain inhibitor compounds |
| US5763576A (en) * | 1995-10-06 | 1998-06-09 | Georgia Tech Research Corp. | Tetrapeptide α-ketoamides |
| US6686335B1 (en) | 1998-09-22 | 2004-02-03 | Cephalon, Inc. | Hydroxamate-containing cysteine and serine protease inhibitors |
| JP4758641B2 (ja) * | 2003-12-12 | 2011-08-31 | 千寿製薬株式会社 | α−ケトアミド誘導体、その製造方法、及びその用途 |
| ATE446948T1 (de) | 2003-12-12 | 2009-11-15 | Senju Pharma Co | Alpha-ketoamidderivativ, herstellungsverfahren und verwendung davon |
| GB2467562A (en) * | 2009-02-06 | 2010-08-11 | Summit Corp Plc | Dual calpain-ROS inhibitors |
-
2015
- 2015-09-08 WO PCT/EP2015/070504 patent/WO2016038040A2/en not_active Ceased
- 2015-09-08 CN CN201580060288.4A patent/CN107001240B/zh active Active
- 2015-09-08 US US15/509,107 patent/US10294269B2/en active Active
- 2015-09-08 EA EA201790537A patent/EA031266B1/ru not_active IP Right Cessation
- 2015-09-08 KR KR1020177009559A patent/KR102404113B1/ko active Active
- 2015-09-08 JP JP2017532211A patent/JP6533580B2/ja active Active
- 2015-09-08 PT PT15766427T patent/PT3191112T/pt unknown
- 2015-09-08 MX MX2017003020A patent/MX374875B/es active IP Right Grant
- 2015-09-08 AU AU2015314292A patent/AU2015314292B2/en not_active Ceased
- 2015-09-08 PE PE2017000419A patent/PE20170918A1/es unknown
- 2015-09-08 ES ES15766427T patent/ES2731274T3/es active Active
- 2015-09-08 BR BR112017004563-0A patent/BR112017004563B1/pt active IP Right Grant
- 2015-09-08 DK DK15766427.7T patent/DK3191112T3/da active
- 2015-09-08 CR CR20170135A patent/CR20170135A/es unknown
- 2015-09-08 EP EP15766427.7A patent/EP3191112B1/en active Active
- 2015-09-08 CA CA2960432A patent/CA2960432C/en active Active
-
2017
- 2017-03-07 CL CL2017000539A patent/CL2017000539A1/es unknown
- 2017-03-07 NI NI201700026A patent/NI201700026A/es unknown
- 2017-03-07 GT GT201700045A patent/GT201700045A/es unknown
- 2017-03-10 SV SV2017005406A patent/SV2017005406A/es unknown
- 2017-03-29 CO CONC2017/0003067A patent/CO2017003067A2/es unknown
- 2017-04-05 EC ECIEPI201721138A patent/ECSP17021138A/es unknown
-
2019
- 2019-05-16 US US16/414,307 patent/US20190270770A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210001A1 (ar) | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 | |
| JP2016516043A5 (enExample) | ||
| SA520411325B1 (ar) | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها | |
| JP2019094345A5 (enExample) | ||
| MX2009008338A (es) | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. | |
| JP2014506907A5 (enExample) | ||
| MY206521A (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| JP2015531773A5 (enExample) | ||
| JP2014500870A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| TN2018000130A1 (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| JP2011037841A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2011526283A5 (enExample) | ||
| JP2016501185A5 (enExample) | ||
| JP2009539943A5 (enExample) | ||
| JP2018531987A5 (enExample) | ||
| MX2014006366A (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| JP2015535847A5 (enExample) | ||
| JP2013514980A5 (enExample) | ||
| JP2011523952A5 (enExample) |